MarketInOut Stock Screener Log In | Sign Up
 

Biogen Inc

MIL • Healthcare • Drug Manufacturers - General • Quote as of 09/09/2026
Biogen Inc stock price and volume chart

Company Profile

IndustryDrug Manufacturers - General
SectorHealthcare
ExchangeMIL
Market Capitalization28,537 mln
Float133 mln
Earnings Date10/30/2026

EPS

4.86
Stretched

P / E

37.30
Overvalued

Piotroski F-Score

3 / 9
Below average

Beneish M-Score

-2.51
Likely reliable

Relative Strength

33 / 100
Underperforming

Debt / Equity

0.44
Low leverage

Business Description

Biogen is a global biopharmaceutical company focused on discovering, developing, and delivering treatments for serious neurological and rare diseases, including multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, and several other conditions. Founded in 1978 and based in Cambridge, Massachusetts, the company markets a broad range of medicines across the United States, Europe, Asia, and beyond. Biogen also works closely with a number of partner organizations to advance new therapies in areas such as gene silencing, rare pediatric diseases, and next-generation drug delivery methods.

Key Fundamentals

EPS4.86
P/E37.30
ROE4.56
ROIC6.75
ROA2.81
Interest Cover6.79
EBITDA, mln1,839
EV / EBITDA18.40
EV / EBIT30.36
Revenue, mln8,624
EV / Revenue3.92

Financial Strength

Altman Z-Score2.95
Piotroski F-Score 3 / 9
Beneish M-Score-2.51
Price to Intrinsic Value0.91
Shiller PE Ratio11.08

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -3.76% 19 / 100   
1 Month 7.46% 83 / 100   
2 Months 12.7% 78 / 100   
6 Months 18.96% 71 / 100   
1 Year 42.99% 78 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us